This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Poniard Pharmaceuticals CEO Discusses Q3 2010 Results - Earnings Call Transcript

Poniard Pharmaceuticals, Inc. ( PARD)

Q3 2010 Earnings Call

November 9, 2010 4:30 PM ET

Executives

Susan Neath – Investor Relations

Ronald Martell – Chief Executive Officer

Mike Jackson – Interim Chief Financial Officer

Dr. Michael Perry – President and Chief Medical Officer

Analysts

Simos Simeonidis – Rodman & Renshaw

Presentation

Operator

Good day. And welcome to the Poniard Pharmaceuticals [Second] Quarter 2010 Earnings Conference Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Susan Neath. Please go ahead, Susan.

Susan Neath

Good afternoon. And thank you for joining us. Poniard issued a press release today, which is available on the company’s website at www.poniard.com. Comments made on this call will contain forward-looking statements relating to, among other things, the commercial potential of the company’s picoplatin and product candidates, the company’s corporate strategies and objectives, regulatory and partnering efforts, product development activity, clinical and regulatory goals, financial condition, future expectations and prospects.

Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of important factors, risks and uncertainties, including the company’s anticipated future operating losses, future capital requirements and ability to obtain future funding, the risks that strategic transactions may not be established on a timely basis on terms that are ultimately favorable to the company or at all, the potential safety, efficacy, and commercial viability of picoplatin, the risk that the company’s additional analysis of data from clinical trials of picoplatin may produce negative or inclusive results, or may be inconsistent with previously announced results or previously conducted trials, the company’s ability to retain key personnel, competition from third parties, the company’s ability to preserve and protect intellectual property rights, the company’s dependence on third-party manufacturers, suppliers, and other contractors, changes in technology, government regulation, and general market conditions, the receipt and timing of FDA and other required regulatory approval, and the other risks and uncertainties described in the company’s reports filed with the Securities and Exchange Commission, including the company’s annual report on Form 10-K for the year ended December 31, 2009, and the company’s Form 10-Q for the quarter ended September 30, 2010.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs